<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We tested the hypothesis that splice site variations in MSH2 and MLH1 are associated with increased risk of hereditary non-<z:e sem="disease" ids="C0334108" disease_type="Neoplastic Process" abbrv="">polyposis</z:e> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (HNPCC) and of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in general in the general population </plain></SENT>
<SENT sid="1" pm="."><plain>In a cohort of 154 HNPCC patients with sequenced MSH2 and MLH1, we identified four possible splice-site mutations, which we subsequently genotyped in more than 9,000 individuals from the general population </plain></SENT>
<SENT sid="2" pm="."><plain>Allele frequencies in the general population were 0 % for 942+3A&gt;T in MSH2, 0.05 % for 307-19A&gt;G, 0.005 % for 1,667+(2-8)del(taaatca);ins(attt), and 4.4 % for 1039-8T&gt;A in MLH1 </plain></SENT>
<SENT sid="3" pm="."><plain>Odds ratios for HNPCC in a case-control design were 419 (95 % CI: 53-18,900) for 942+3A&gt;T in MSH2, 19 (5-72) for 307-19A&gt;G, 194 (21-1,768) for 1,667+(2-8)del(taaatca); ins(attt), and 0.3 (0.1-0.7) for 1,039-8T&gt;A in MLH1 </plain></SENT>
<SENT sid="4" pm="."><plain>In the general population, incidence rate ratios for 1,039-8T&gt;A carriers versus noncarriers were 0.70 (0.51-0.96) for HNPCC-related <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> combined and 0.82 (0.71-0.94) for <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> combined in a prospective design </plain></SENT>
<SENT sid="5" pm="."><plain>The three rare mutations were associated with increased risk of HNPCC </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, the more common 1,039-8T&gt;A associated with a decreased risk of HNPCC, of HNPCC-related <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> combined in the general population </plain></SENT>
<SENT sid="7" pm="."><plain>These findings are novel and important in the counseling of HNPCC patients and their relatives </plain></SENT>
</text></document>